Quick Answer
Coherus Oncology, Inc. reported Cash and Equivalents of $88.88 million for fiscal year 2025.
Coherus Oncology, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $88.88M | -29.5% |
| 2024 | $125.99M | +22.4% |
| 2023 | $102.89M | +61.9% |
| 2022 | $63.55M | -84.8% |
| 2021 | $417.19M | -22.9% |
| 2020 | $541.16M | +204.6% |
| 2019 | $177.67M | +145.5% |
| 2018 | $72.36M | -43.0% |
| 2017 | $126.91M | +1.6% |
| 2016 | $124.95M | -21.0% |
| 2015 | $158.23M | +5.2% |
| 2014 | $150.39M | +280.2% |
| 2013 | $39.55M | +171.9% |
| 2012 | $14.55M | +89.3% |
| 2011 | $7.68M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $103.35M | +5.8% | -52.3% |
| June 30, 2025 | $216.89M | +36.2% | +163.2% |
| March 31, 2025 | $82.41M | -68.3% | -34.6% |
| December 31, 2024 | $125.99M | +22.4% | +29.0% |
| September 30, 2024 | $97.69M | +21.7% | -38.7% |
| June 30, 2024 | $159.24M | +118.4% | -38.7% |
| March 31, 2024 | $259.77M | +1509.0% | +152.5% |
| December 31, 2023 | $102.89M | +61.9% | +28.2% |
- Coherus Oncology, Inc. showed a decrease of -29.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2011–2025 period, Coherus Oncology, Inc.’s cash and equivalents has grown by 1056.7% (from $7.68 million to $88.88 million).
- The most recent figure is from Coherus Oncology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: